| Literature DB >> 27737951 |
Elisa Fabbri1,2, Chee W Chia3, Richard G Spencer3, Kenneth W Fishbein3, David A Reiter3, Donnie Cameron1, Ariel C Zane1, Zenobia A Moore1, Marta Gonzalez-Freire1, Marco Zoli2, Stephanie A Studenski1, Rita R Kalyani4, Josephine M Egan3, Luigi Ferrucci5.
Abstract
Whether individuals with insulin resistance (IR) but without criteria for diabetes exhibit reduced mitochondrial oxidative capacity is unclear; addressing this question could guide research for new therapeutics. We investigated 248 participants without diabetes from the Baltimore Longitudinal Study of Aging (BLSA) to determine whether impaired mitochondrial capacity is associated with prediabetes, IR, and duration and severity of hyperglycemia exposure. Mitochondrial capacity was assessed as the postexercise phosphocreatine recovery time constant (τPCr) by 31P-magnetic resonance spectroscopy, with higher τPCr values reflecting reduced capacity. Prediabetes was defined using the American Diabetes Association criteria from fasting and 2-h glucose measurements. IR and sensitivity were calculated using HOMA-IR and Matsuda indices. The duration and severity of hyperglycemia exposure were estimated as the number of years from prediabetes onset and the average oral glucose tolerance test (OGTT) 2-h glucose measurement over previous BLSA visits. Covariates included age, sex, body composition, physical activity, and other confounders. Higher likelihood of prediabetes, higher HOMA-IR, and lower Matsuda index were associated with longer τPCr. Among 205 participants with previous OGTT data, greater severity and longer duration of hyperglycemia were independently associated with longer τPC In conclusion, in individuals without diabetes a more impaired mitochondrial capacity is associated with greater IR and a higher likelihood of prediabetes.Entities:
Mesh:
Year: 2016 PMID: 27737951 PMCID: PMC5204309 DOI: 10.2337/db16-0754
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461
Characteristics of the sample population according to prediabetes status
| Normal ( | Prediabetes ( | ||
|---|---|---|---|
| Age (years) | 73.3 ± 10.1 | 73.9 ± 8.9 | 0.570 |
| Male sex | 55 (37.2) | 60 (60) | <0.001 |
| Caucasian race | 110 (74.3) | 69 (69) | 0.388 |
| Education (years) | 18 (16–18) | 17 (16–18) | 0.627 |
| Weight (kg) | 71.5 ± 13.2 | 79.1 ± 13.9 | <0.001 |
| Height (cm) | 165.2 ± 8.2 | 169.2 ± 9.4 | <0.001 |
| BMI (kg/m2) | 26.1 ± 3.8 | 27.5 ± 3.7 | 0.005 |
| TBFM (DEXA-measured), kg | 23.9 ± 8.7 | 27.8 ± 9.3 | <0.001 |
| Body fatness (TBFM/weight | 33 ± 9 | 35 ± 9 | 0.154 |
| Waist circumference (cm) | 86.6 ± 11.7 | 93.5 ± 11.1 | <0.001 |
| Trunk FM (kg) | 11.05 ± 4.9 | 14.5 ± 5.3 | <0.001 |
| Smokers (former or current) | 55 (37.2) | 47 (47) | 0.148 |
| Physical activity (MET-min/day) | 311 (165.5–490.5) | 243.0 (133.5–445.0) | 0.104 |
| IL-6 (pg/mL) | 3.9 (3.1–5) | 4 (3.3–5.1) | 0.494 |
| CRP (μg/mL) | 0.99 (0.47–2.49) | 0.95 (0.50–2.50) | 0.841 |
| Leptin (ng/mL) | 11.3 (5.2–20.6) | 11.2 (5.3–19.4) | 0.843 |
| Adiponectin (μg/mL) | 13.4 (7.7–21.4) | 12.7 (5.4–18.4) | 0.164 |
| Fasting glucose (mg/dL) | 91.1 ± 8.7 | 102.2 ± 11.6 | <0.001 |
| OGTT 2-h glucose (mg/dL) | 105.7 ± 26.5 | 141.8 ± 39.4 | <0.001 |
| Homa IR units | 1.31 (0.95–1.76) | 1.91 (1.27–2.96) | <0.001 |
| Matsuda index | 5.72 (4.07–7.75) | 3.96 (2.59–5.66) | <0.001 |
| Reduced Matsuda index | 7.62 (5.09–10.5) | 4.28 (2.77–7.47) | <0.001 |
| Previous BLSA visits with OGTT data ( | 3 (2–4) | 4 (3–5) | <0.001 |
| Severity of exposure to hyperglycemia (average OGTT 2-h glucose, mg/dL, from previous BLSA visits) | 104.2 ± 19.0 | 134.5 ± 27.5 | <0.001 |
| 48.9 (42.4–56.8) | 53.4 (53.4–47.7) | 0.001 | |
| %PCr depletion | 34.7 (27.7–45.7) | 35.2 (27.4–45.1) | 0.959 |
Values are reported as the mean ± SD, n (%), or median (interquartile range).
*HOMA index (IR) = [fasting glucose (mg/dL) × fasting insulin (mU/L)]/405.
**Matsuda index (insulin sensitivity) = 10,000/√[(fasting glucose × fasting insulin) × (mean OGTT glucose concentration × mean OGTT insulin concentration).
***Reduced time points − Matsuda index (Reduced Matsuda Index) (insulin sensitivity) = 10,000/√[(fasting glucose × fasting insulin) × (OGTT 2-h glucose × OGTT 2-h insulin).
Figure 1Unadjusted median values and range of τPCr (in seconds) according to the presence of prediabetes, IR (HOMA index), and insulin sensitivity (Matsuda index and reduced Matsuda index).
Results from multivariate logistic models testing the association between τPCr (s) and likelihood (odds ratio) of having prediabetes or being in a higher tertile of HOMA index, Matsuda index, and reduced Matsuda index
| Likelihood of prediabetes | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model I (age, sex, and %PCr depletion adjusted) ( | Model II | Model III | ||||||||||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||||||||||||
| 1.05 (1.03–1.08) | <0.001 | 1.06 (1.02–1.09) | <0.001 | 1.06 (1.03–1.10) | <0.001 | |||||||||||
| Model IV | Model V | Model VI | Model VII | |||||||||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |||||||||||||
| 1.07 (1.03–1.10) | <0.001 | 1.06 (1.03–1.09) | <0.001 | 1.05 (1.02–1.09) | <0.001 | 1.06 (1.03–1.09) | <0.001 | |||||||||
| Higher tertile of HOMA index (IR) | ||||||||||||||||
| Model I (age, sex, and %PCr depletion adjusted) ( | Model II | Model III | ||||||||||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||||||||||||
| 1.04 (1.01–1.06) | 0.002 | 1.04 (1.01–1.07) | 0.002 | 1.04 (1.01–1.07) | 0.003 | |||||||||||
| Model IV | Model V | Model VI | Model VII | |||||||||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |||||||||||||
| 1.05 (1.02–1.08) | 0.001 | 1.04 (1.01–1.07) | 0.003 | 1.03 (1.01–1.06) | 0.015 | 1.05 (1.02–1.08) | 0.001 | |||||||||
| Higher tertile of Matsuda index (insulin sensitivity) | ||||||||||||||||
| Model I (age, sex, and %PCr depletion adjusted) ( | Model II | Model III | ||||||||||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||||||||||||
| 0.96 (0.94–0.98) | 0.001 | 0.96 (0.93–0.99) | 0.004 | 0.96 (0.93–0.99) | 0.003 | |||||||||||
| Model IV | Model V | Model VI | Model VII | |||||||||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |||||||||||||
| 0.95 (0.92–0.98) | 0.001 | 0.96 (0.93–0.98) | 0.003 | 0.97 (0.94–0.99) | 0.011 | 0.95 (0.93–0.98) | 0.001 | |||||||||
| Higher tertile of reduced Matsuda index (insulin sensitivity) | ||||||||||||||||
| Model I (age, sex, and %PCr depletion adjusted) ( | Model II | Model III | ||||||||||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||||||||||||
| 0.95 (0.93–0.97) | <0.001 | 0.95 (0.92–0.98) | <0.001 | 0.95 (0.92–0.98) | <0.001 | |||||||||||
| Model IV | Model V | Model VI | Model VII | |||||||||||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |||||||||||||
| 0.94 (0.92–0.97) | <0.001 | 0.95 (0.92–0.98) | <0.001 | 0.96 (0.93–0.98) | 0.001 | 0.95 (0.92–0.97) | <0.001 | |||||||||
OR, odds ratio.
*Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body weight, body height, and DEXA-measured trunk FM.
§Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body weight, body height, DEXA-measured trunk FM, and plasma levels of IL-6, CRP, leptin, and adiponectin.
†Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body height, body weight, waist circumference, and plasma levels of IL-6, CRP, leptin, and adiponectin.
#Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body weight, body height, DEXA-measured TBFM, and plasma levels of IL-6, CRP, leptin, and adiponectin.
**Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body height, percentage of body fatness, and plasma levels of IL-6, CRP, leptin, and adiponectin.
‡Age, sex, %PCr depletion, race, education, smoking status, physical activity level, BMI, and plasma levels of IL-6, CRP, leptin, and adiponectin.
Results from multivariate regression models testing the association between τPCr and severity (average OGTT 2-h glucose, in mg/dL, from previous BLSA visits) and/or duration (years from the onset of prediabetes) of hyperglycemia exposure (both included as predictors in the same model)
| Model I (age, sex, and %PCr depletion adjusted) ( | Model II | Model III | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| β (SE) | β (SE) | β (SE) | ||||||||||
| Severity of hyperglycemia exposure (mg/dL) | 0.05 (0.03) | 0.042 | 0.05 (0.03) | 0.059 | 0.05 (0.03) | 0.055 | ||||||
| Duration of hyperglycemia exposure (years) | 0.16 (0.07) | 0.019 | 0.16 (0.07) | 0.019 | 0.16 (0.07) | 0.023 | ||||||
| Model IV | Model V | Model VI | Model VII | |||||||||
| β (SE) | β (SE) | β (SE) | β (SE) | |||||||||
| Severity of hyperglycemia exposure (mg/dL) | 0.06 (0.03) | 0.026 | 0.05 (0.03) | 0.051 | 0.05 (0.03) | 0.064 | 0.06 (0.03) | 0.034 | ||||
| Duration of hyperglycemia exposure (years) | 0.17 (0.07) | 0.013 | 0.14 (0.07) | 0.037 | 0.15 (0.07) | 0.028 | 0.16 (0.06) | 0.017 | ||||
Participants with available longitudinal data on OGTT from previous visits were 205 in 248.
*Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body weight, body height, DEXA-measured trunk FM.
§Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body weight, body height, DEXA-measured trunk FM, and plasma levels of IL-6, CRP, leptin, and adiponectin.
†Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body height, body weight, waist circumference, and plasma levels of IL-6, CRP, leptin, and adiponectin.
#Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body weight, body height, DEXA-measured TBFM, and plasma levels of IL-6, CRP, leptin, and adiponectin.
‡Age, sex, %PCr depletion, race, education, smoking status, physical activity level, body height, percentage of body fatness, and plasma levels of IL-6, CRP, leptin, and adiponectin.
**Age, sex, %PCr depletion, race, education, smoking status, physical activity level, BMI, and plasma levels of IL-6, CRP, leptin, and adiponectin.